Literature DB >> 19127447

Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.

Merav Bahat-Stroomza1, Yael Barhum, Yossef S Levy, Olga Karpov, Shlomo Bulvik, Eldad Melamed, Daniel Offen.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder with its motor phenomena due mostly to loss of dopamine-producing neurons in the substantia nigra. Pharmacological treatments aimed to increase the deficient dopaminergic neurotransmission are effective in ameliorating the cardinal symptoms, but none of these therapies is curative. It has been suggested that treatment with neurotrophic factors (NTFs) might protect and prevent death of the surviving dopaminergic neurons and induce proliferation of their axonal nerve terminals with reinnervations of the deafferented striatum. However, long-term delivery of such proteins into the CNS is problematic. We therefore aimed to differentiate ex vivo human bone marrow-derived mesenchymal stromal cells into astrocyte-like cells, capable of generating NTFs for future transplantation into basal ganglia of PD patients. Indeed, mesenchymal stromal cells treated with our novel astrocyte differentiation medium, present astrocyte-like morphology and express the astrocyte markers S100beta, glutamine synthetase and glial fibrillary acidic protein. Moreover, these astrocyte-like cells produce and secrete significant amounts of glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain-derived neurotrophic factor as indicated by messenger RNA, real-time polymerase chain reaction, ELISA, and Western blot analyses. Such NTF-producing cells transplanted into the striatum of 6-hydroxydopamine-lesioned rats, a model of PD, produced a progressive reduction in the apomorphine-induced contralateral rotations as well as behavioral improvement in rotor-rod and the "sunflower seeds" eating motor tests. Histological assessments revealed that the engrafted cells survived and expressed astrocyte and human markers and acted to regenerate the damaged dopaminergic nerve terminal system. Findings indicate that our novel procedure to induce NTF-producing astrocyte-like cells derived from human bone marrow stromal cells might become a promising and feasible autologous transplantation strategy for PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127447     DOI: 10.1007/s12031-008-9166-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  42 in total

Review 1.  Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.

Authors:  Liang-Wei Chen; Kin-Lam Yung; Ying-Shing Chan
Journal:  Curr Drug Targets       Date:  2005-11       Impact factor: 3.465

2.  Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation.

Authors:  Jie Deng; Bryon E Petersen; Dennis A Steindler; Marda L Jorgensen; Eric D Laywell
Journal:  Stem Cells       Date:  2005-12-01       Impact factor: 6.277

Review 3.  Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Authors:  Yossef S Levy; Merav Stroomza; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

4.  Protection of nigral neurons by GDNF-engineered marrow cell transplantation.

Authors:  K W Park; M A Eglitis; M M Mouradian
Journal:  Neurosci Res       Date:  2001-08       Impact factor: 3.304

5.  GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons.

Authors:  K Nakajima; H Hida; Y Shimano; I Fujimoto; T Hashitani; M Kumazaki; T Sakurai; H Nishino
Journal:  Brain Res       Date:  2001-10-19       Impact factor: 3.252

6.  Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

Authors:  J H Kordower; S Palfi; E Y Chen; S Y Ma; T Sendera; E J Cochran; E J Cochran; E J Mufson; R Penn; C G Goetz; C D Comella
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

7.  Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.

Authors:  Lingling Lu; Chunli Zhao; Yujun Liu; Xiaohong Sun; Chunli Duan; Man Ji; Huanying Zhao; Qunyuan Xu; Hui Yang
Journal:  Brain Res Brain Res Protoc       Date:  2005-04-22

Review 8.  Pathogenic role of glial cells in Parkinson's disease.

Authors:  Peter Teismann; Kim Tieu; Oren Cohen; Dong-Kug Choi; Du Chu Wu; Daniel Marks; Miquel Vila; Vernice Jackson-Lewis; Serge Przedborski
Journal:  Mov Disord       Date:  2003-02       Impact factor: 10.338

9.  Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner.

Authors:  Marta Salinas; Raquel Diaz; Nader G Abraham; Carlos M Ruiz de Galarreta; Antonio Cuadrado
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

10.  Gene expression patterns in in vivo normal adult astrocytes compared with cultured neonatal and normal adult astrocytes.

Authors:  Takao Nakagawa; Joan P Schwartz
Journal:  Neurochem Int       Date:  2004 Jul-Aug       Impact factor: 3.921

View more
  30 in total

Review 1.  Neurotrophins in lung health and disease.

Authors:  Ys Prakash; Michael A Thompson; Lucas Meuchel; Christina M Pabelick; Carlos B Mantilla; Syed Zaidi; Richard J Martin
Journal:  Expert Rev Respir Med       Date:  2010-06       Impact factor: 3.772

Review 2.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 3.  Regenerative therapy for neuronal diseases with transplantation of somatic stem cells.

Authors:  Hiroshi Kanno
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 4.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

Review 5.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

6.  Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.

Authors:  Yonit Fisher-Shoval; Yael Barhum; Ofer Sadan; Shlomit Yust-Katz; Tali Ben-Zur; Nirit Lev; Chen Benkler; Moshe Hod; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2012-05-26       Impact factor: 3.444

7.  Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Authors:  Yael Barhum; Sharon Gai-Castro; Merav Bahat-Stromza; Ran Barzilay; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-11-10       Impact factor: 3.444

Review 8.  Mesenchymal stem cell-based therapy.

Authors:  Vaibhav Mundra; Ivan C Gerling; Ram I Mahato
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

9.  Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.

Authors:  Jianjun Wu; Wenbo Yu; Yan Chen; Yaru Su; Zhengtong Ding; Huimin Ren; Yuping Jiang; Jian Wang
Journal:  Neurochem Res       Date:  2009-11-06       Impact factor: 3.996

Review 10.  Emerging role of S100B protein implication in Parkinson's disease pathogenesis.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Cell Mol Life Sci       Date:  2020-10-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.